Balancing Trained Immunity with Persistent Immune Activation and the Risk of Simian Immunodeficiency Virus Infection in Infant Macaques Vaccinated with Attenuated Mycobacterium tuberculosis or Mycobacterium bovis BCG Vaccine

Medientyp: E-Artikel
Titel: Balancing Trained Immunity with Persistent Immune Activation and the Risk of Simian Immunodeficiency Virus Infection in Infant Macaques Vaccinated with Attenuated Mycobacterium tuberculosis or Mycobacterium bovis BCG Vaccine
Beteiligte: Jensen, Kara; dela Pena-Ponce, Myra Grace; Piatak, Michael; Shoemaker, Rebecca; Oswald, Kelli; Jacobs, William R.; Fennelly, Glenn; Lucero, Carissa; Mollan, Katie R.; Hudgens, Michael G.; Amedee, Angela; Kozlowski, Pamela A.; Estes, Jacob D.; Lifson, Jeffrey D.; Van Rompay, Koen K. A.; Larsen, Michelle; De Paris, Kristina
Erschienen: American Society for Microbiology, 2017
Erschienen in: Clinical and Vaccine Immunology
Sprache: Englisch
DOI: 10.1128/cvi.00360-16
ISSN: 1556-6811; 1556-679X
Schlagwörter: Microbiology (medical) ; Clinical Biochemistry ; Immunology ; Immunology and Allergy
Entstehung:
Anmerkungen:
Beschreibung: <jats:title>ABSTRACT</jats:title><jats:p>Our goal is to develop a pediatric combination vaccine to protect the vulnerable infant population against human immunodeficiency virus type 1 (HIV-1) and tuberculosis (TB) infections. The vaccine consists of an auxotroph<jats:named-content content-type="genus-species">Mycobacterium tuberculosis</jats:named-content>strain that coexpresses HIV antigens. Utilizing an infant rhesus macaque model, we have previously shown that this attenuated<jats:named-content content-type="genus-species">M. tuberculosis</jats:named-content>(A<jats:italic>Mtb</jats:italic>)-simian immunodeficiency virus (SIV) vaccine is immunogenic, and although the vaccine did not prevent oral SIV infection, a subset of vaccinated animals was able to partially control virus replication. However, unexpectedly, vaccinated infants required fewer SIV exposures to become infected compared to naive controls. Considering that the current TB vaccine,<jats:named-content content-type="genus-species">Mycobacterium bovis</jats:named-content>bacillus Calmette-Guérin (BCG), can induce potent innate immune responses and confer pathogen-unspecific trained immunity, we hypothesized that an imbalance between enhanced myeloid cell function and immune activation might have influenced the outcome of oral SIV challenge in A<jats:italic>Mtb</jats:italic>-SIV-vaccinated infants. To address this question, we used archived samples from unchallenged animals from our previous A<jats:italic>Mtb</jats:italic>-SIV vaccine studies and vaccinated additional infant macaques with BCG or A<jats:italic>Mtb</jats:italic>only. Our results show that vaccinated infants, regardless of vaccine strain or regimen, had enhanced myeloid cell responses. However, CD4<jats:sup>+</jats:sup>T cells were concurrently activated, and the persistence of these activated target cells in oral and/or gastrointestinal tissues may have facilitated oral SIV infection. Immune activation was more pronounced in BCG-vaccinated infant macaques than in A<jats:italic>Mtb</jats:italic>-vaccinated infant macaques, indicating a role for vaccine attenuation. These findings underline the importance of understanding the interplay of vaccine-induced immunity and immune activation and its effect on HIV acquisition risk and outcome in infants.</jats:p>
Zugangsstatus: Freier Zugang

Nur in Feld suchen:

Zuletzt gesuchte Begriffe: